证券代码：430047 证券简称：诺思兰德 公告编号：2025-016 北京诺思兰德生物技术股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 23 日 2.会议召开地点：北京市海淀区上地开拓路 5 号 A406 室会议室 3.会议召开方式：现场及通讯方式 4.发出董事会会议通知的时间和方式：2025 年 4 月 11 日以书面方式发出 5.会议主持人：董事长许松山先生 6.会议列席人员：监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次董事会的召集、召开和议案审议程序符合《公司法》及《公司章程》 的有关规定，表决结果合法有效。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事许日山、陈垒、王英典、徐辉、任自力因公差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于<2024 年度总经理工作报告>的议案》 1.议案内容： 公 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于北京诺思兰德生物技术股份有限公司 2024 年度营业收入扣除事项的 专项审核报告 中国·北京 BEIJING CHINA 目 录 | 一、专项审核报告 | 1-2 | | --- | --- | | 二、2024年度营业收入扣除情况明细表 | 3 | . . . . China Audit Asia Pacific Certified Public Accountants LLP 关于北京诺思兰德生物技术股份有限公司 2024 年度营业收入扣除事项的专项审核报告 中审亚太审字(2025)003465 号 北京诺思兰德生物技术股份有限公司全体股东: 我们接受委托,在审计了北京诺思兰德生物技术股份有限公司(以下简称"诺 思兰德")2024年12月31日的合并及公司资产负债表,2024年度的合并及公司 利润表、合并及公司现金流量表和合并及公司股东权益变动表以及财务报表附注 的基础上,审核了后附的《北京诺思兰德生物技术股份有限公司 2024 年度营业 收入扣除情 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 北京诺思兰德生物技术股份有限公司 内部控制审计报告 中国·北京 BEIJING CHINA (特殊普通合伙) . . . . . China Audit Asia Pacific Certified Public Accountants LLP. 内部控制审计报告 中审亚太审字(2025)003463 号 北京诺思兰德生物技术股份有限公司全体股东: 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发 表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由 于情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度 降低,根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为,诺思兰德于 2024年 12月 31 日按照《企业内部控制基本规 范》和相关规定在所有重大方面保持了有效的财务报告内部控 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 北京诺思兰德生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项说明 中国·北京 BEIJING CHINA 所（特殊普通合伙） 北京诺恩兰德生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 中审亚太审字(2025)003478 号 北京诺思兰德生物技术股份有限公司全体股东: 我们接受委托,在审计了北京诺思兰德生物技术股份有限公司(以下简称"诺 思兰德") 2024 年 12 月 31 日的合并及公司资产负债表,2024 年度的合并及公 司利润表、合并及公司现金流量表和合并及公司股东权益变动表以及财务报表附 注,出具了中审亚太审字(2025)003408 号标准无保留意见审计报告的基础上, 对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总 表》(以下简称"汇总表")进行了专项审核。 按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 -- 上市公 司资金往来、对外担保的监管要求》(证 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 AUDIT REPORT 北京诺思兰德生物技术股份有限公司 2024 年度财务报表审计 中国·北京 BEIJING CHINA 目 录 | 一、审计报告 | 1-5 | | --- | --- | | 二、已审财务报表 | | | 1．合并资产负债表 | 6-7 | | 2．合并利润表 | 8 | | 3．合并现金流量表 | 9 | | 4．合并股东权益变动表 | 10-11 | | 5．资产负债表 | 12-13 | | 6．利润表 | 14 | | 7．现金流量表 | 15 | | 8．股东权益变动表 | 16-17 | | 9．财务报表附注 | 18-91 | . . . . China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 中审亚太审字(2025)003408 号 北京诺恩兰德生物技术股份有限公司全体股东: 一、审计意见 我们审计了北京诺思兰德生物技术股 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于北京诺思兰德生物技术股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 中国·北京 BEIJING CHINA . . . . China Audit Asia Pacific Certified Public Accountants LLP. 关于北京诺思兰德生物技术股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 中审亚太审字(2025)003477 号 北京诺思兰德生物技术股份有限公司全体股东: 我们接受委托,对后附的北京诺思兰德生物技术股份有限公司(以下简称"诺 思兰德") 截至 2024 年 12 月 31 日止的《2024 年度募集资金存放与实际使用情 况的专项报告》进行了鉴证工作。 按照北京证券交易所颁布的《北京证券交易所股票上市规则(试行)》《北 京证券交易所上市公司持续监管指引第 9 号一募集资金管理》等相关规定,编制 《2024 年度募集资金存放和实际使用情况的专项报告》,提供真实、合法、完整 的实物证据、原始书面材料、副 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-026 北京诺思兰德生物技术股份有限公司 2024 年度独立董事述职报告（徐辉） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为北京诺思兰德生物技术股份有限公司（以下简称"公司"）的独立 董事，2024 年度，本人严格按照《公司法》、《证券法》、《上市公司独立董 事管理办法》及《北京证券交易所上市公司持续监管指引第 1 号——独立董事》 等有关法律、法规及《独立董事工作制度》和《公司章程》的相关规定和要求， 认真履行独立董事职责，及时了解公司的经营状况，按时出席公司召开的相关会 议并认真审议各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事 的作用，切实维护了公司和全体股东特别是中小股东的合法权益。现将本人 2024 年履职情况报告如下： 一、个人基本情况 本人现就职于北京兴华会计师事务所（特殊普通合伙），任合伙人。2020 年 6 月至今，任公司独立董事，兼任公司董事会审计委员会委员、董事会薪酬与 考核委员会委员。 20 ...

Financial Performance - Net profit attributable to shareholders was CNY -7,716,806.44, an improvement from CNY -12,250,307.09 in the same period last year[10] - Operating revenue increased by 1.85% to CNY 16,420,451.13 compared to CNY 16,121,526.48 in the previous year[10] - The company's basic earnings per share improved to CNY -0.03 from CNY -0.05 in the previous year[10] - The weighted average return on net assets based on net profit attributable to shareholders was -2.36%, an improvement from -4.13% in the same period last year[10] - Net loss for Q1 2025 was ¥6,783,601.29, an improvement compared to a net loss of ¥11,280,541.80 in Q1 2024[34] - Comprehensive loss for Q1 2025 totaled ¥7,043,386.09, compared to a comprehensive loss of ¥11,521,154.71 in Q1 2024[34] - Total comprehensive income for Q1 2025 was -8,742,195.99, an improvement from -13,593,141.73 in Q1 2024, showing a reduction in comprehensive losses by about 35.5%[38] Assets and Liabilities - Total assets decreased by 8.63% to CNY 436,312,529.93 compared to the end of the previous year[10] - The company's asset-liability ratio decreased to 14.45% from 20.36% year-on-year[10] - Total current assets amounted to CNY 174,502,470.71 as of March 31, 2025, compared to CNY 237,983,211.85 on December 31, 2024, reflecting a decrease of approximately 26.7%[27] - Non-current assets totaled CNY 261,810,059.22 as of March 31, 2025, up from CNY 239,550,794.49 on December 31, 2024, indicating an increase of about 9.3%[28] - Total liabilities decreased from CNY 97,217,059.37 on December 31, 2024, to CNY 63,038,969.05 as of March 31, 2025, a reduction of about 35.2%[29] - The company's equity attributable to shareholders decreased from CNY 331,442,284.06 on December 31, 2024, to CNY 323,465,692.82 as of March 31, 2025, a decline of approximately 2.9%[29] Cash Flow - Cash flow from operating activities was CNY -18,923,393.62, a significant decline from CNY -5,456,755.62 in the same period last year[10] - Cash flow from operating activities for Q1 2025 was -18,923,393.62, worsening from -5,456,755.62 in Q1 2024[39] - Cash flow from investment activities for Q1 2025 was -78,630,405.71, compared to -158,861,228.05 in Q1 2024, indicating a decrease in cash outflow by approximately 50.5%[40] - The cash inflow from financing activities amounted to $224.20 million, with a net cash flow of $214.11 million after outflows[43] - The net increase in cash and cash equivalents was -$38.77 million, contrasting with an increase of $50.06 million in the prior period[43] Shareholder Information - The total number of ordinary shares outstanding at the end of the reporting period was 274,271,974, with 65.67% held by the controlling shareholder[16] - The top ten shareholders collectively held 127,690,083 shares, representing 46.56% of total shares, with no shareholder pledging or freezing their shares[18][20] - The number of ordinary shareholders was 7,446 at the end of the reporting period[17] Research and Development - Research and development expenses decreased by 45.17% to CNY 6,627,675.84 due to reduced expenses related to ongoing projects[13] - Research and development expenses for Q1 2025 were ¥6,627,675.84, a decrease from ¥12,088,644.58 in Q1 2024, indicating a potential shift in investment strategy[33] - Research and development expenses for Q1 2025 were 5,593,288.44, down from 11,464,739.20 in Q1 2024, a reduction of about 51.1%[37] Government Support and Other Income - The company received government subsidies amounting to CNY 135,089.18, related to personal income tax refund projects[14] - Non-recurring gains and losses totaled CNY 359,433.64, with a net amount of CNY 288,011.76 after tax impacts and minority interests[14] - The company reported a fair value change gain of CNY 235,139.66 from financial assets and liabilities[14] Compliance and Governance - The company has not disclosed any major litigation or arbitration matters during the reporting period[23] - There were no significant related party transactions or fund misappropriation incidents reported[23] - The company has complied with all internal review procedures for significant events and disclosed them in a timely manner[23] - The company has not undergone any accounting policy changes or error corrections during the reporting period[15]

Financial Performance - The company's operating revenue for 2024 reached ¥72,110,862.43, representing a year-over-year increase of 20.84% compared to ¥59,675,141.95 in 2023[31]. - The gross profit margin improved to 54.40% in 2024, up from 49.20% in 2023[31]. - The net loss attributable to shareholders decreased to ¥45,180,740.62 in 2024 from ¥48,134,821.42 in 2023[31]. - Total assets increased by 45.54% to ¥477,534,006.34 at the end of 2024, compared to ¥328,120,719.02 at the end of 2023[33]. - Total liabilities decreased by 26.07% to ¥97,217,059.37 at the end of 2024, down from ¥131,496,996.06 at the end of 2023[33]. - The net assets attributable to shareholders surged by 116.33% to ¥331,442,284.06 at the end of 2024, compared to ¥153,212,884.84 at the end of 2023[33]. - The company reported a basic earnings per share of -0.17 in 2024, an improvement from -0.19 in 2023[31]. - The cash flow from operating activities showed a net outflow of ¥39,782,131.84 in 2024, compared to an outflow of ¥37,613,636.33 in 2023[33]. - The company received government subsidies amounting to ¥10,479,843.04 in 2024, which is an increase from ¥8,778,416.79 in 2023[38]. - Non-recurring gains and losses totaled ¥13,449,893.54 in 2024, compared to ¥9,359,988.38 in 2023[39]. Share Issuance and Capital Structure - In January 2024, the company issued 16,106,071 shares of common stock at a price of RMB 14.33 per share, raising a total of RMB 230,799,997.43[8]. - The company has a total of 274,271,974 shares of common stock outstanding[23]. - The company’s total number of shares decreased to 274,271,974 after the cancellation of stock options and restricted shares[142]. - The company repurchased and canceled 602,000 shares of restricted stock at a price of RMB 4.30 per share, totaling RMB 2,588,600[145]. - The company raised a total of CNY 247,583,028.98 through public offerings, with a net amount of CNY 229,007,628.31 after deducting issuance costs[166]. - The company has a remaining balance of 124,395,588.51 RMB from the raised funds as of December 31, 2024[162]. - The company plans to use the raised funds for drug research and development, biological engineering new drug projects, and to replenish working capital[162]. Research and Development - The company has 11 biopharmaceutical projects in the pipeline, including 5 gene therapy drugs and 6 recombinant protein drugs, with the core project NL003 having completed Phase III clinical trials and submitted a drug registration application for ulcer indications[42]. - The company has established core technology platforms for gene therapy, recombinant proteins, and ophthalmic drugs, enhancing its R&D capabilities[51]. - R&D expenditure for the current period is CNY 43,566,589.92, representing 60.42% of operating revenue, a decrease from 72.88% in the previous period[98]. - The company has 64 R&D personnel, accounting for 35.56% of total employees, an increase from 57 personnel in the previous period[101]. - The company is in the early evaluation stage for a gene therapy product aimed at treating osteoarthritis, indicating a commitment to innovative treatment options[104]. - The company is developing multiple new products, including RD3001 for dry eye syndrome and RD3002 for ptosis, both of which are in the research phase[104]. - The company has not capitalized any R&D expenditures, maintaining a 0% capitalization rate[98]. Market and Product Development - The company is focused on expanding its market presence with innovative products aimed at addressing unmet medical needs[104]. - The company is in the process of launching several new eye care products, including RD3003, RD3004, and RD4001, which are expected to enhance competitiveness and profitability[105]. - The company is developing a new product, RD4005, for the treatment of dry eye disease, with significant market potential as there are currently no similar products available domestically[106]. - The company is also working on RD4006, aimed at alleviating symptoms of dry eyes and visual fatigue, which will further diversify its product line[106]. - The company is in the national review stage for several products, including RD4001 and RD4002, which are expected to have a broad market outlook[105]. Regulatory and Compliance - The company received a registration acceptance notice for NL003 from the National Medical Products Administration in July 2024, marking a step towards domestic production approval[9]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its annual report[14]. - The company has established a comprehensive quality management system and drug vigilance system to ensure drug quality throughout its lifecycle[117]. - The company is committed to establishing a compliance management system to strengthen business compliance oversight and improve overall operational efficiency[126]. - The company has received a clean audit report from Zhongshui Yatai Accounting Firm, confirming its financial integrity and compliance with regulations[113]. Strategic Initiatives - A new subsidiary was established in Shanghai in August 2024, aimed at enhancing the company's strategic planning and commercialization efforts[9]. - The company is focusing on the commercialization of NL003, including building a sales operation system and expanding the sales team to increase market share[125]. - The company is actively optimizing its management processes and has passed inspections for drug production license additions, enhancing its operational compliance and risk management[47]. - The company is committed to expanding its market share by actively exploring target markets and ensuring drug efficacy meets clinical needs[124]. Industry Context - The pharmaceutical manufacturing industry is expected to maintain stable growth, driven by an aging population and increasing chronic disease management needs, with over 210 million people aged 65 and above in China[121]. - The national medical insurance drug list now includes 3,159 drugs, significantly boosting the innovation drive within the pharmaceutical industry[194]. - The cumulative savings from centralized drug procurement since 2018 have reached approximately 161.4 billion yuan, demonstrating substantial cost efficiency[194]. - The government work report emphasizes the promotion of innovative drugs, marking a significant policy shift in the healthcare sector[193]. Risks and Challenges - The company acknowledges uncertainties in macro policies affecting drug registration, pricing, and market access, which could impact its operational strategies[128]. - The company faces risks related to the lengthy and complex drug development process, which may lead to delays in project timelines and potential failures in achieving development goals[129]. - The company is actively seeking to expand its ophthalmic drug pipeline and enhance sales and CDMO service market promotion to mitigate ongoing losses[130].